Attruby (acoramidis), a near complete TTR stabilizer, has been approved by FDA to reduce cardiovascular death and ...
2025 will be a very eventful year for BridgeBio. In addition to the commercial launches of Attruby in the United States, ...
The price is close to the average $225,000 annual cost of Pfizer's drugs, before any discounts or rebates, although, ...
BridgeBio shares climbed by nearly 25% Monday on news its drug for a cardiac form of transthyretin amyloidosis was approved ...
BridgeBio Pharma snagged FDA approval for its rival to Pfizer's heart disease treatment, Vyndaqel. BridgeBio stock catapulted ...
On a Zoom call last month from California, BridgeBio CEO Neil Kumar needled a colleague about the remote possibility of the ...
We project BridgeBio's key drug candidate, Attruby (acoramidis), could achieve global sales of around $3.3 billion by 2033. Attruby is an oral drug designed to treat transthyretin amyloid ...
TipRanks on MSN9d
BridgeBio announces FDA approved Attruby for ATTR-CM patientsPharma announced that the U.S. Food and Drug Administration approved Attruby, an orally-administered near-complete stabilizer ...
BridgeBio, the drug’s maker, will be offering a patient support program called ForgingBridges to U.S. patients prescribed Attruby and their families to help them get the therapy with insurance ...
GlobalData on MSN7d
FDA approves BridgeBio’s Attruby for ATTR-CM treatmentThe US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis), an oral transthyretin (TTR) ...
The U.S. Food and Drug Administration has approved BridgeBio's drug for a rare and deadly heart condition, the company said ...
The US Food and Drug Administration (FDA) has approved BridgeBio Pharma’s Attruby (acoramidis) to treat adults with ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback